title: Biological characterization of cyclothialidine, a new DNA gyrase inhibitor.
abstract: Cyclothialidine is a new DNA gyrase inhibitor isolated from Streptomyces filipinensis NR0484. Structurally, it belongs to a new class of natural products containing a unique 12-membered lactone ring that is partly integrated into a pentapeptide chain. Cyclothialidine was found to be one of the most active of all the DNA gyrase inhibitors tested in the DNA supercoiling reaction of Escherichia coli DNA gyrase; 50% inhibitory concentrations (in micrograms per milliliter) of 0.03 (cyclothialidine), 0.06 (novobiocin), 0.06 (coumermycin A1), 0.66 (norfloxacin), 0.88 (ciprofloxacin), and 26 (nalidixic acid) were found. In addition, DNA gyrases from gram-positive species were inhibited equally as well as DNA gyrase from E. coli. Cyclothialidine also inhibited the in vitro DNA replication directed from oriC of E. coli. Among the bacterial species tested, only Eubacterium spp. were inhibited by cyclothialidine, suggesting that it can enter the cells of Eubacterium and exert antibacterial activity through interference with the DNA gyrase within the cells, although its penetration into most bacterial cells appears to be poor. These results provide a basis for cyclothialidine to be a lead structure for novel antibacterial agents with DNA gyrase inhibitory activities.
authors.affiliation: Nippon Roche Research Center, Kamakura, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Nakada
authors.forename: H
authors.initials: H
authors.lastname: Shimada
authors.forename: T
authors.initials: T
authors.lastname: Hirata
authors.forename: Y
authors.initials: Y
authors.lastname: Aoki
authors.forename: T
authors.initials: T
authors.lastname: Kamiyama
authors.forename: J
authors.initials: J
authors.lastname: Watanabe
authors.forename: M
authors.initials: M
authors.lastname: Arisawa
mesh_terms: D000818:Animals; D001420:Bacteria, Aerobic / Q000187:drug effects; D001421:Bacteria, Anaerobic / Q000187:drug effects; D001426:Bacterial Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002417:Cattle; D004247:DNA / Q000378:metabolism; D004261:DNA Replication / Q000187:drug effects; D004250:DNA Topoisomerases, Type II / Q000378:metabolism; D004278:DNA, Superhelical / Q000187:drug effects / Q000378:metabolism; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D006367:HeLa Cells; D006571:Heterocyclic Compounds / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D019384:Nucleic Acid Synthesis Inhibitors; D010456:Peptides, Cyclic; D011758:Pyrroles / Q000494:pharmacology*; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors
chemical_list: D001426:Bacterial Proteins; D004278:DNA, Superhelical; D006571:Heterocyclic Compounds; D019384:Nucleic Acid Synthesis Inhibitors; D010456:Peptides, Cyclic; D011758:Pyrroles; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; C085889:cyclothialidine; D004247:DNA; D012321:DNA-Directed RNA Polymerases; D004250:DNA Topoisomerases, Type II